RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I did not ask him specifically about Ampakines, which would have been tantamount to asking about Cortex, since no other company had a regulatory 'problem' vis-a-vis Ampakines. And I had provided numerous other questions that I either asked in person or were asked in a group setting by a moderator: that particular topic felt like it would cross a boundary.

OT (ACAD): To me the schizophrenia angle is dose-sparing in order to reduce side effects, especially weight-gain. I think this will get off-label use, albeit more likely on an outpatient basis, since inpatient units have formulary inclusion issues and often simply receive a daily preset amount of reimbursement from insurors, and they don't want to add the cost of a new branded drug. But if a psychiatrist has outpatients who respond best to Zyprexa, but blow up weight-wise, adding pimavanserin to see if the weight-gain can be ameliorated is something that some will try. And if they try it and are successful, this could spread.

There have not been any noteworthy additions to the sz tx options other than reformulations. The programs seeking to add nicotinic alpha7 or glycinergic drugs for the sake of impacting cognitive/negative symptoms are the 'next big thing', and the most advanced are in Phase III.

NP